Physician profile
Amber Portier Littlefield
NPI 1538440094
$224,534.83
in general payments reported to CMS, 2019-2025
31 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,589 · 2022: $3,793 · 2023: $43K · 2024: $82K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Honoraria: $65K · Consulting Fee: $57K · Food and Beverage: $13K · Travel and Lodging: $12K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,050.00 |
| Honoraria | $65,166.50 |
| Consulting Fee | $57,364.00 |
| Food and Beverage | $12,928.83 |
| Travel and Lodging | $11,631.52 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $133,637.97 | 2023-2025 | Auvelity |
| Abbvie INC. | $81,734.30 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,097.34 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,081.06 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Alkermes, INC. | $1,034.85 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $972.25 | 2021-2022 | |
| Corium, LLC | $598.96 | 2022-2025 | Azstarys |
| Lundbeck LLC | $505.28 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $500.73 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $491.45 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Tris Pharma INC | $462.40 | 2022-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $353.98 | 2023-2025 | Xelstrym, Secuado |
| Braeburn INC. | $322.54 | 2023-2024 | Brixadi |
| Vanda Pharmaceuticals INC. | $243.80 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $231.26 | 2022-2024 | Aplenzin, Wellbutrin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $230.46 | 2021-2025 | Trintellix |
| Indivior INC. | $222.06 | 2022-2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $161.00 | 2021-2023 | Qelbree |
| Eisai INC. | $123.29 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.21 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $79.54 | 2023-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $65.32 | 2023 | Austedo Xr |
| Merck Sharp & Dohme LLC | $60.95 | 2022-2023 | Belsomra |
| Neos Therapeutics, Lp | $54.03 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Jazz Pharmaceuticals INC. | $36.66 | 2021-2022 | |
| Sage Therapeutics, LLC | $35.06 | 2024 | |
| Collegium Pharmaceutical, INC. | $17.01 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $17.00 | 2023 | Xelstrym |
| Almatica Pharma LLC | $16.27 | 2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $13.53 | 2024 | Quviviq |
| Adlon Therapeutics L.P. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Littlefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.